

## SEMINAIRE

*Auditorium Fernand Gallais (bât. LCC)  
Campus CNRS, 205 route de Narbonne TOULOUSE*

\*\*\*\*\*

**Lundi 17 septembre 2007 à 11 h.**

**Dr Ronald P. TAYLOR** (Department of Biochemistry and molecular dynamics, University of Virginia Health System, Charlottesville, Virginia)

***" Rituximab Induces Shaving of CD20 on Targeted B Cells in Chronic Lymphocytic Leukemia : The Cutting Edge of Antigenic Modulation "***

- In vitro/in vivo: RTX promotes complement (C) activation and C3b deposition on B cells.
- Clinical study: The standard dose of RTX leads to shaving of the CD20 target for almost all CLL patients.
- Pilot patient study: Much lower, more frequent doses of RTX promote slow but continued clearance of malignant cells with much less shaving of target CD20.
- Shaving can be recapitulated in vitro and in a mouse model.
- Generalization of shaving: Antigenic modulation and trogocytosis.
- If a patient is treated with large doses of a mAb that targets cancer cells, what are the consequences of saturation/exhaustion of effector mechanisms required for killing the cells?
- Can shaving be blocked, but killing mechanisms preserved ?

Contact : Denis Hudrisier

\*\*\*\*\*